TAE Life Sciences has announced a distribution agreement with alphaXRT, a premier provider of advanced radiation therapy technologies. Under this partnership, alphaXRT will distribute TAE Life Sciences’ Alphabeam™ BNCT system and novel boron drugs, while also providing associated services across Australia and New Zealand.| TAE Life Sciences
TAE Life Sciences has announced a distribution agreement with alphaXRT, a premier provider of advanced radiation therapy technologies. Under this partnership, alphaXRT will distribute TAE Life Sciences’ Alphabeam™ BNCT system and novel boron drugs, while also providing associated services across Australia and New Zealand.| TAE Life Sciences
TAE Life Sciences, in collaboration with Kyoto University and Principal Investigator Dr. Fuyuhiko Tamanoi, is thrilled to announce groundbreaking preclinical results in Boron Neutron Capture Therapy (BNCT). Utilizing TAE Life Science’s novel boron-10 drugs and Kyoto University Research Reactor (KURR) neutron source has generated significant pre-clinical data that may redefine the potential of BNCT in cancer treatment. The post TAE Life Sciences and Kyoto University Achieve Breakthrough Prec...| TAE Life Sciences
TAE Life Sciences (TLS), a leader in developing boron neutron capture therapy (BNCT) technology and associated innovative boron target drugs, and Stella Pharma, the pioneering developer of boronophenylalanine (BPA) under the product name, Steboronine®, for BNCT, are pleased to announce a strategic collaboration focused on the development, commercialization and expansion of BNCT using BPA in the United States and European markets. The post TAE Life Sciences and Stella Pharma Announce Strategi...| TAE Life Sciences
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India).| TAE Life Sciences
We are thrilled to announce the addition of Dr. Deepak “Dee” Khuntia, M.D., FASTRO, to the esteemed Board of Directors at TAE Life Sciences. Dr. Khuntia's vast expertise in radiation oncology and his significant contributions to advancing cancer treatment technologies significantly reinforce our company’s dedication to pioneering advancements in the field.| TAE Life Sciences
TAE Life Sciences, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption.| TAE Life Sciences
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.| TAE Life Sciences
Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.| TAE Life Sciences
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.| TAE Life Sciences
